Business Wire

Transition Industries LLC and Mitsubishi Gas Chemical announce Letter of Intent for a long-term Methanol Sales Agreement from the Pacifico Mexinol project in Sinaloa, Mexico

Share

Transition Industries LLC announced that it has signed a Letter of Intent (LOI) with Mitsubishi Gas Chemical Company, Inc. (MGC) to enter into a long-term Methanol Sales Agreement (MSA). Under the MSA, Transition Industries intends to supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2028. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. The terms of the LOI and MSA were not disclosed.

When it initiates operations, Pacifico Mexinol is expected to be the largest single ultra-low carbon chemicals facility in the world - producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture.

Rommel Gallo, CEO of Transition Industries, commented: “We are pleased to announce our Letter of Intent for a long-term Methanol Sales Agreement with Mitsubishi Gas Chemical Company, one of the leading manufacturers and marketers of chemicals in the world. We are honored to work with MGC in our joint efforts to address climate change and supply the Pacific Basin with ultra-low carbon methanol.”

Masahiko Naito, Division Director, C1 Chemicals Division for Mitsubishi Gas Company, said: “As one of the major producers and suppliers of methanol globally, Mitsubishi Gas Chemical prioritizes the acceleration to lower carbon intensity of our methanol supply and aims to contribute to a sustainable world. I’m very excited to work with Transition Industries towards this goal and to bring value to society.”

Pacifico Mexinol is expected to break ground in early 2025 and begin commercial operations in 2028.

About Mitsubishi Gas Company

Mitsubishi Gas Chemical Company is a unique technology-oriented manufacturer producing more than 90% of its products using proprietary technologies. Committing itself to creating new technology and value, MGC boasts a broad range of products, from basic chemicals such as methanol, xylene, hydrogen peroxide, to high-performance products such as engineering plastics, materials for printed wiring board and oxygen absorbers. MGC will contribute to societal growth and harmony by creating a wide range of value through chemistry.

About Transition Industries

Transition Industries LLC, based in Houston, Texas, is a developer of world-scale net-zero carbon emissions methanol and hydrogen projects in North America to address climate change and promote environmental and social sustainability. For additional information about Pacifico Mexinol or Transition Industries, email inquiries@transitionind.com.

About IFC

IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2024, IFC committed a record $56 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit www.ifc.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241028970837/en/

Contacts

inquiries@transitionind.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release

Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage

The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 17:58:00 EEST | Press release

Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the 12th edition of the IBSA Foundation Fellowship The € 32,000 fellowships were awarded to research projects in five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy aging/regenerative medicine. In particular, this latter category has attracted growing interes

Rigaku Completes New Building at Yamanashi Plant27.5.2025 17:00:00 EEST | Press release

Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two key objectives in mind. One objective is to further reinforce the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye